Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 177)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 31.03.24 12:32:14 von
neuester Beitrag 31.03.24 12:32:14 von
Beiträge: 1.796
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 4
Gesamt: 149.334
Gesamt: 149.334
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: 1YI1
0,6200
EUR
+12,73 %
+0,0700 EUR
Letzter Kurs 22.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
21.05.24 · globenewswire  |
25.04.24 · globenewswire |
28.03.24 · globenewswire |
14.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2460 | +49,94 | |
| 1,0800 | +28,56 | |
| 2,1800 | +27,49 | |
| 1,9900 | +20,61 | |
| 10.777,50 | +19,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 46,20 | -16,00 | |
| 0,5701 | -16,77 | |
| 2,5100 | -17,43 | |
| 2,2001 | -20,57 | |
| 0,5989 | -37,61 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 55.923.251 von Steel21x am 10.10.17 20:12:42das sind die stücke die wieder gekauft hat. Er hat aber auch scho vorher gekaut (siehe wer Thread eröffnet hat) und hat somit einen neuen EP, welcher mich interessieren würde. gruss
Antwort auf Beitrag Nr.: 55.923.065 von julfi am 10.10.17 19:53:49Hat er doch schon geschrieben....im Schnitt 1,90 ......Man muss hier auch ein wenig Geduld haben. Ich habe auch nur ne kleine Position drinnen. Die hoffentlich mal groß wird 😉
Antwort auf Beitrag Nr.: 55.896.622 von Biohero am 06.10.17 15:55:15der wert hat wirklich ein grosses potential, WENN alles so kommt wie es sollte... überlege mir einzusteigen. Was hast du für einen EP, biohero, wenn ich fragen darf?
■Q4 2017 – Top-line results from Phase III kidney function trial.
Die Ergebnisse können jederzeit eintreffen im Q4, wie sehen hier die Chancen aus?
Gruss
Die Ergebnisse können jederzeit eintreffen im Q4, wie sehen hier die Chancen aus?
Gruss
Antwort auf Beitrag Nr.: 55.896.622 von Biohero am 06.10.17 15:55:15Hab das direkt aus dem TNXP board kopiert weil das auch hier bei dieser low float aktie gut passt .
Wer hier investiert ist sollte bitte seine Aktien zu einem höheren kurs z.b. $10 unter GTC zum verkauf reinstellen .Der grund dafür ist das es angeblich so hilft seine Aktien vor shorts zu schützen aber noch wichtiger ist das die Aktien am Markt nicht verfügbar sein sollen was natürlich für noch größere Kurssprünge sorgen könnte besonders bei solchen low floater wie TNXP .Ich hab oft gesagt das ich wirklich nicht weiß ob das funktioniert es wird mir nur so erzählt aber solange es nichts kostet kann man das doch ruhig machen . Danke .
How to Prevent your Shares Holdings from being Shorted
http://www.contracts-for-difference.com/Borrowing-lending-sh…
Wer hier investiert ist sollte bitte seine Aktien zu einem höheren kurs z.b. $10 unter GTC zum verkauf reinstellen .Der grund dafür ist das es angeblich so hilft seine Aktien vor shorts zu schützen aber noch wichtiger ist das die Aktien am Markt nicht verfügbar sein sollen was natürlich für noch größere Kurssprünge sorgen könnte besonders bei solchen low floater wie TNXP .Ich hab oft gesagt das ich wirklich nicht weiß ob das funktioniert es wird mir nur so erzählt aber solange es nichts kostet kann man das doch ruhig machen . Danke .
How to Prevent your Shares Holdings from being Shorted
http://www.contracts-for-difference.com/Borrowing-lending-sh…
Trading Spotlight
Riskante Aktie aber Potential is Heftig hier hab ein paar im schnitt bei $1.90 wieder gekauft .
Kitov Announces FDA Acceptance of NDA for KIT-302
https://www.baystreet.ca/articles/research_reports/lifesci/K…
KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib
monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.
Expected Upcoming Milestones
■Q4 2017 – Top-line results from Phase III kidney function trial.
■Q2 2018 – Expected FDA approval decision for KIT-302.
Kitov Announces FDA Acceptance of NDA for KIT-302
https://www.baystreet.ca/articles/research_reports/lifesci/K…
KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib
monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.
Expected Upcoming Milestones
■Q4 2017 – Top-line results from Phase III kidney function trial.
■Q2 2018 – Expected FDA approval decision for KIT-302.
Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock
- Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS.
- NT219 is a first-in-class drug candidate presenting a new paradigm of cancer treatment - overcoming tumors' cancer drug resistance.
TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the acquisition of an additional 27% stake in TyrNovo Ltd., a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders. As announced on January 13, 2017, Kitov had acquired a controlling interest, which is now approximately 65% of TyrNovo. After the closing of this transaction, Kitov will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares.
Following negotiations with a group of unaffiliated minority shareholders who collectively hold approximately 27%, of TyrNovo, the Company has entered into an agreement to acquire their shares based on an agreed upon TyrNovo valuation of $7 million. In exchange for these TyrNovo shares, Kitov will issue 13,169,689 new shares (equivalent to 658,484 American Depositary Shares or ADSs) of Kitov, at an agreed upon price, in excess of prevailing market prices, of $2.50 per ADS.
"Since early 2017, NT219 demonstrated impressive efficacy results including in combination with Keytruda®, where it converted non-responding tumors to responders and blocked tumor progression in an immuno-oncology preclinical model. We are pleased to have negotiated the opportunity for Kitov to increase its stake in TyrNovo. We are committed to the development of NT219, which we believe is a highly attractive asset for Kitov's shareholders in the growing field of oncology" stated Mr. Isaac Israel, Chief Executive Officer. "We believe that expanding our ownership in TyrNovo provides a significant opportunity for further growth of Kitov and added value to our shareholders."
"Based on the pre-clinical results generated to date, we are receiving solid preliminary interest from potential strategic partners for NT219, which presents a novel, first-in-class mechanism of action in the oncology field."
About NT219
NT219 is a small molecule that presents a new concept in cancer therapy by promoting the degradation and the phosphorylation of two oncology-related checkpoints, Insulin Receptor Substrates (IRS) 1 and signal transducer and activator of transcription 3 (STAT3), respectively. While targeted anti-cancer drugs inhibit the "ON" signal, NT219 activates the "OFF" switch, extensively blocking major oncogenic pathways. In pre-clinical trials, NT219, in combination with several approved cancer drugs, displayed potent anti-tumor effects and increased survival in various cancers by preventing the tumors from developing -drug resistance and reversing resistance after it has been acquired. In combination with various approved oncology drugs, NT219 demonstrated potent anti-tumor effects and increased survival in various cancer models including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers, through the prevention of acquired resistance and regression of resistant tumors.
About TyrNovo
TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.
About Kitov Pharmaceuticals
Kitov Pharmaceuticals (NASDAQ: KTOV, TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoint for its Phase III clinical trial. Kitov's newest drug, NT219, which is developed by its majority-owned subsidiary, TyrNovo Ltd., is a small molecule that presents a new concept in cancer therapy, and in combination with various approved oncology drugs, demonstrated potent anti-tumor effects and increased survival in various cancer models. By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.
- Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS.
- NT219 is a first-in-class drug candidate presenting a new paradigm of cancer treatment - overcoming tumors' cancer drug resistance.
TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the acquisition of an additional 27% stake in TyrNovo Ltd., a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders. As announced on January 13, 2017, Kitov had acquired a controlling interest, which is now approximately 65% of TyrNovo. After the closing of this transaction, Kitov will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares.
Following negotiations with a group of unaffiliated minority shareholders who collectively hold approximately 27%, of TyrNovo, the Company has entered into an agreement to acquire their shares based on an agreed upon TyrNovo valuation of $7 million. In exchange for these TyrNovo shares, Kitov will issue 13,169,689 new shares (equivalent to 658,484 American Depositary Shares or ADSs) of Kitov, at an agreed upon price, in excess of prevailing market prices, of $2.50 per ADS.
"Since early 2017, NT219 demonstrated impressive efficacy results including in combination with Keytruda®, where it converted non-responding tumors to responders and blocked tumor progression in an immuno-oncology preclinical model. We are pleased to have negotiated the opportunity for Kitov to increase its stake in TyrNovo. We are committed to the development of NT219, which we believe is a highly attractive asset for Kitov's shareholders in the growing field of oncology" stated Mr. Isaac Israel, Chief Executive Officer. "We believe that expanding our ownership in TyrNovo provides a significant opportunity for further growth of Kitov and added value to our shareholders."
"Based on the pre-clinical results generated to date, we are receiving solid preliminary interest from potential strategic partners for NT219, which presents a novel, first-in-class mechanism of action in the oncology field."
About NT219
NT219 is a small molecule that presents a new concept in cancer therapy by promoting the degradation and the phosphorylation of two oncology-related checkpoints, Insulin Receptor Substrates (IRS) 1 and signal transducer and activator of transcription 3 (STAT3), respectively. While targeted anti-cancer drugs inhibit the "ON" signal, NT219 activates the "OFF" switch, extensively blocking major oncogenic pathways. In pre-clinical trials, NT219, in combination with several approved cancer drugs, displayed potent anti-tumor effects and increased survival in various cancers by preventing the tumors from developing -drug resistance and reversing resistance after it has been acquired. In combination with various approved oncology drugs, NT219 demonstrated potent anti-tumor effects and increased survival in various cancer models including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers, through the prevention of acquired resistance and regression of resistant tumors.
About TyrNovo
TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.
About Kitov Pharmaceuticals
Kitov Pharmaceuticals (NASDAQ: KTOV, TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoint for its Phase III clinical trial. Kitov's newest drug, NT219, which is developed by its majority-owned subsidiary, TyrNovo Ltd., is a small molecule that presents a new concept in cancer therapy, and in combination with various approved oncology drugs, demonstrated potent anti-tumor effects and increased survival in various cancer models. By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.
Antwort auf Beitrag Nr.: 55.864.111 von Biohero am 02.10.17 13:11:22Na, ich dachte es geht gen Norden.
Auch hier gute Nachrichten heute NDA wurde akzeptiert aktie steigt um über 11% in pre-mkt .
Kitov Announces Filing by FDA of New Drug Application for KIT-302
https://finance.yahoo.com/news/kitov-announces-filing-fda-dr…
In connection with its determination that Kitov's application is sufficiently complete to permit a substantive review, the FDA, under the Prescription Drug User Fee Act (PDUFA), has set a target date of May 31, 2018 to complete its review.
Kitov Announces Filing by FDA of New Drug Application for KIT-302
https://finance.yahoo.com/news/kitov-announces-filing-fda-dr…
In connection with its determination that Kitov's application is sufficiently complete to permit a substantive review, the FDA, under the Prescription Drug User Fee Act (PDUFA), has set a target date of May 31, 2018 to complete its review.
Website wieder online, seit kurzem. Könnte jetzt kurz vor News stehen.
Durchsuchen
